2023
Mechanisms of liver fibrosis in metabolic syndrome
Mehal W. Mechanisms of liver fibrosis in metabolic syndrome. EGastroenterology 2023, 1: e100015. PMID: 37946713, PMCID: PMC10634657, DOI: 10.1136/egastro-2023-100015.Peer-Reviewed Original ResearchNon-alcoholic steatohepatitisLiver fibrosisMetabolic syndromeHepatic stellate cellsHepatocellular injuryImmune systemHSC transdifferentiationGrowth factorChronic hepatocellular injuryInnate immune cellsMetabolite changesInnate immune systemAdaptive immune systemNASH fibrosisHepatocellular damageAntifibrotic strategiesImmune cellsProfibrotic roleT cellsFree fatty acidsStellate cellsViral infectionFibrosisSyndromeEndothelial cells
2020
S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series
Mankash M, Kelly M, Mehal W, Do A. S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series. The American Journal Of Gastroenterology 2020, 115: s518-s519. DOI: 10.14309/01.ajg.0000706112.69854.c1.Peer-Reviewed Original Research
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplications
2015
Antifibrotic Therapies in the Liver
Mehal W, Schuppan D. Antifibrotic Therapies in the Liver. Seminars In Liver Disease 2015, 35: 184-198. PMID: 25974903, PMCID: PMC5743222, DOI: 10.1055/s-0035-1550055.Peer-Reviewed Original ResearchConceptsAntifibrotic therapyIdeal patient populationRegression of fibrosisBest noninvasive methodFibrolytic propertiesDose titrationClinical outcomesFibrosis regressionPulmonary fibrosisPatient populationCombination therapyLiver fibrosisIndividualized therapyEncouraging dataFibrotic responseTherapeutic targetDrug AdministrationFibrosisTherapyNoninvasive methodInterindividual heterogeneityCell populationsAntifibroticsLiverFibrolysis
2010
Cell Death and Fibrogenesis
Mehal W, Imaeda A. Cell Death and Fibrogenesis. Seminars In Liver Disease 2010, 30: 226-231. PMID: 20665375, PMCID: PMC3219753, DOI: 10.1055/s-0030-1255352.BooksConceptsHepatic stellate cellsQuiescent hepatic stellate cellsChronic liver injuryNatural killer cellsCell deathHIV infectionLiver injuryNK cellsKiller cellsAntifibrotic effectsImmune suppressionImmune cellsProfibrotic effectsStellate cellsHepatocyte deathHSC apoptosisDeathCellular deathFibrosisCellular debrisMatrix depositionHSC deathSurvival signalsApoptotic bodiesProapoptotic signals
2007
The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis
Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.Peer-Reviewed Original ResearchHepatic fibrosisChronic liver diseaseRole of inflammationWound healing responseViral hepatitisLiver diseaseFibrosis progressionAutoimmune diseasesChronic injuryLiver fibrosisCellular sourceFibrosisExtracellular matrixDiseaseRealistic expectationsUbiquitous responseMajor advancesTranscriptional eventsHepatitisInflammationPatientsPathophysiologyPathogenesisInjuryLiver